Avexa, formed in 2004, is an Australian drug-discovery company based in Melbourne, Victoria.
Avexa's business is the discovery and development of anti-infective pharmaceutical medicines for the treatment of serious human infectious diseases.
Avexa's principal research programs focus on the discovery of innovative medicines for the treatment of the diseases caused by:
Each of these programs represents an area of significant medical need and high market potential and is designed to discover and develop innovative compounds which have a competitive edge.
The Avexa Board of Directors is committed to implementing and maintaining the highest standards of good corporate governance and best practice with the initial objective of working towards compliance with the recommendations published by the Australian Securities Exchange (ASX Guidelines).
The Avexa Board is responsible for, and has the authority to determine, all matters relating to the strategic direction, policies and practices for the management and operation of the Company.
In view of the small capitalisation of the Company and prior to the establishment of a Board comprised of a majority of independent non-executive Directors, the Avexa Board has determined in certain instances to depart from the ASX Guidelines as detailed in Section 5 of the Information Memorandum in relation to the spin-out of shares in Avexa Ltd dated 5 July 2004. Click here to view the Information Memorandum.
Avexa welcomes comments from shareholders in relation to the Company's Corporate Governance program. Use the online enquiry form to forward any comments.
Avexa has developed guidelines which provide a basic explanation of insider trading and Avexa's policy to prevent it. Avexa's policy for directors and all employees in respect of the purchase and sale of Company securities prohibits trading whilst they are in possession of price sensitive information.
Avexa's commercial strategy is to focus on realizing the value in its internal projects in the area of anti-infectives by achieving definitive, well established milestones for each project. Avexa aims to progress its projects as far as possible (at least to the end of proof-of-concept in man) to add maximum value but would consider discussions with potential partners for collaborations in specific areas to expedite project progress.
Avexa has an extensive foundation of experience in anti-infective drug discovery and development and is keen to exploit its expertise through new collaborations in the anti-infectives area. Avexa has much to offer and would be pleased to explore specific opportunities for collaboration on new anti-infectives research projects, particularly in the anti-viral space.
Avexa believes its expertise in drug development coupled with its passion to advance anti-infectives projects as effectively as possible make Avexa an excellent choice for projects in need of focused development. Avexa would be pleased to discuss what we can offer an external project, ranging from playing a limited role, co-development, risk sharing, or full in-licensing.